Testing NEO100 given through the nose for children's high grade gliomas
Original title: A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and find the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called NEO100, given through the nose, in young people with a fast growing brain tumor.
Who this trial is for. This trial is for patients with a type of fast growing brain tumor called a pediatric type diffuse high grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. It tests whether NEO100, given through the nose, is safe, what dose to use, and whether it reaches the tumor.
Where it stands. The trial is looking at safety and the right dose. It is also checking if the drug gets into the tumor. This is only checked in tumor tissue left over from a surgery or biopsy that doctors had already planned. The trial has not reported results yet.
What this means, and what it doesn't
What it could mean: Researchers are trying a new way to get a drug to a brain tumor, through the nose. If your child has this kind of tumor, you could ask the care team if this trial might fit. The trial team decides who can join.
What it doesn't mean: This trial is a test, not a proven treatment. Joining does not mean the drug will help. It is not a cure, and it is not a promise of one.
Source: ClinicalTrials.gov, September 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.